% of Cases treated with Teletherapy
| Country average (population) | Country average (country) | England | Scotland | Wales1 | Northern Ireland | Republic of Ireland | |
|---|---|---|---|---|---|---|---|
| All invasive xnmsc | 19.8% | 20.5% | 19.8% | NA | 19.5% | 22.3% | |
| All xnmsc 0-24 | 12.5% | 12.9% | 12.5% | NA | 10.6% | 15.5% | |
| All xnmsc 25-59 | 22.7% | 23.9% | 22.6% | NA | 24.6% | 24.5% | |
| All xnmsc 60-79 | 21.9% | 21.5% | 22.0% | NA | 21.1% | 21.4% | |
| All xnmsc 80+ | 11.8% | 11.5% | 11.8% | NA | 11.1% | 11.6% | |
| Haematology | 9.0% | 9.3% | 9.1% | NA | 7.4% | 11.6% | |
| Head and Neck | 60.1% | 59.7% | 60.2% | NA | 59.4% | 59.6% | |
| Lower GI | 12.9% | 13.0% | 12.9% | NA | 11.6% | 14.4% | |
| Upper GI | 18.1% | 15.8% | 18.3% | NA | 21.0% | 8.2% | |
| HPB | 2.1% | 3.1% | 1.9% | NA | 2.7% | 4.7% | |
| Trachea, Bronchus & Lung | 26.4% | 26.4% | 26.3% | NA | 28.2% | 24.6% | |
| Melanoma of skin | 0.8% | 0.7% | 0.8% | NA | 0.6% | 0.9% | |
| Breast | 37.6% | 37.0% | 37.6% | NA | 38.6% | 34.8% | |
| Prostate | 40.9% | 47.3% | 40.3% | NA | 42.4% | 59.1% | |
| Cervix | 9.2% | 13.1% | 8.7% | NA | 13.7% | 16.9% | |
| Other Female Genitals | 18.6% | 16.5% | 19.0% | NA | 11.9% | 18.5% | |
| Kidney | 5.3% | 7.1% | 5.1% | NA | 7.1% | 9.0% | |
| Bladder | 17.6% | 16.9% | 17.7% | NA | 17.0% | 16.0% | |
| Brain and CNS | 48.0% | 44.7% | 48.5% | NA | 42.5% | 43.0% | |
| Thyroid & other endocrine glands | 8.8% | 15.1% | 8.0% | NA | 16.9% | 20.4% | |
| CUP | 11.5% | 10.2% | 11.6% | NA | 11.8% | 7.1% | |
| Other invasive cancer | 11.6% | 11.1% | 11.7% | NA | 10.0% | 11.5% | |
| Breast in situ | 32.3% | 34.3% | 32.1% | NA | 29.9% | 41.1% | |
| Cervix in situ | 0.0% | 0.1% | 0.0% | NA | 0.2% | 0.0% | |
| Other tumours | 1.1% | 1.5% | 0.9% | NA | 1.3% | 2.4% | |
| Non-Melanoma Skin Cancer | 1.8% | 1.3% | 1.9% | NA | 1.1% | 0.8% |